Armata Pharmaceuticals, Inc.
Extracted from this filing and checked against the source text.
Armata Pharmaceuticals, Inc. amended Voting Agreement Amendment with Innoviva, Inc. and Innoviva Strategic Opportunities LLC (effective 2026-01-23).
On January 23, 2026, the Company, Innoviva and Innoviva Sub entered into an amendment (the “Voting Agreement Amendment”) to that certain Second Amended and Restated Voting Agreement, dated February 9, 2022, by and among the Company, Innoviva and Innoviva SubView on SEC.gov
Armata Pharmaceuticals, Inc. amended Credit Agreement Amendments with Innoviva Strategic Opportunities LLC (effective 2026-01-23).
On January 23, 2026, Armata Pharmaceuticals, Inc. (the “Company”) entered into amendments (collectively, the “Credit Agreement Amendments”) to four existing credit agreements, each as previously amended, with Innoviva Strategic Opportunities LLC (“Innoviva Sub”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company (“Innoviva”).View on SEC.gov
Armata Pharmaceuticals, Inc. amended Warrant Amendment with Innoviva Strategic Opportunities LLC (effective 2026-01-23).
On January 23, 2026, the Company and Innoviva Sub entered into an amendment (the “Warrant Amendment”) to four outstanding warrant certificates previously issued by the Company to Innoviva Sub.View on SEC.gov
197 material agreements filed in the last 30 days. Browse all material agreements →
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.